FDA Rejects Capricor's Deramiocel Application, Citing Weak Evidence
FDA issued a Complete Response Letter on Capricor's resubmitted Deramiocel filing, citing weak evidence of effectiveness and other clinical gaps.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The US Food and Drug Administration has issued a Complete Response Letter on Capricor Therapeutics' resubmitted filing for Deramiocel. The agency pointed to insufficient evidence of effectiveness and other clinical shortcomings, according to TradingView, which cites GlobeNewswire.
The company said it held about $198.5 million in cash and securities as of September 30, 2026, enough, in its view, to fund at least 12 months of planned operations. Capricor is reviewing the letter and will determine its next regulatory steps. The release does not specify the deficiencies, so the scope of any required work remains unclear. The company is also reviewing operating costs to extend its runway.
why it matters
For Capricor shares this is a major setback, since approval of its lead candidate is now blocked. The next key event will be the company's assessment of the letter and its disclosure of specific regulatory steps. Investors will watch the time and money needed to address the FDA's concerns.
market impact
Акции Capricor: отказ FDA блокирует одобрение ведущего препарата — давление на бумаги
- Capricor shares (CAPR) pressure down — a rejection by the FDA blocks approval of the lead candidate
tags
instruments
on polymarket
sources
- Capricor Therapeutics (CAPR) Receives FDA Rejection of Deramiocel Application — TradingView, 21 November 2026 at 00:55 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗